Notification about latest news from us.
Moderna forecasts a substantial revenue dip for 2025, causing share prices to plunge while the firm accelerates cost-cutting efforts amidst dwindling vaccine demand.
Moderna is nearing completion of a vaccine for norovirus as cases surge, potentially marking a significant advancement in public health.
By clicking send you'll receive occasional emails from newsletters about this topic.